DR. RONALD N GERMAIN, M.D.
Osteopathic Medicine at Crossing Creek Rd, Rockville, MD
License number
Maryland D37914
Category
Osteopathic Medicine
Type
General Practice
Address
Address
10404 Crossing Creek Rd, Rockville, MD 20854
Phone
(301) 983-2712
Personal information
See more information about RONALD N GERMAIN at radaris.comName
Address
Phone
10404 Crossing Creek Rd, Potomac, MD 20854
10404 Crossing Creek Rd, Potomac, MD 20854
Professional information
Dr. Ronald N Germain, Potomac MD - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
10404 Crossing Creek Rd, Potomac 20854
(301) 983-2712 (Phone)
(301) 983-2712 (Phone)
Certifications:
Pediatrics, 1954
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1976
Boston Medical Center
Albany Hosp
Strong Memorial Hospital
Harvard Medical School
Graduated: 1976
Boston Medical Center
Albany Hosp
Strong Memorial Hospital
Method To Induce Cytotoxic T Lymphocytes Specific For A Broad Array Of Hiv-1 Isolates Using Hybrid Synthetic Peptides
US Patent:
5711947, Jan 27, 1998
Filed:
Jul 23, 1993
Appl. No.:
8/095332
Inventors:
Jay A. Berzofsky - Bethesda MD
Hidemi Takahashi - Tokyo, JP
Ronald N. Germain - Potomac MD
Hidemi Takahashi - Tokyo, JP
Ronald N. Germain - Potomac MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Wahington DC
and Human Services - Wahington DC
International Classification:
A61K 3921, A61K 3912, C12P 2106, C07K 100
US Classification:
4241881
Abstract:
The instant invention describes the synthesis of short peptides, corresponding to the amino acid residues of the V3 loop of the gp160 envelope glycoprotein of HIV-1 numbered 315 to 329 by Ratner (Ratner, L. et al. , Nature 313, 277 (1985)) in the strain IIIB, wherein the residue corresponding to number 325 in HIV-1 IIIB is substituted by the homologous residue from another clinical isolate or strain. The invention further describes the use of said peptides in pharmaceutical compositions and an immunization protocol which elicits cytotoxic T cells reactive to a broad range of isolates of HIV-1.
Method To Induce Cytotoxic T Lymphocytes Specific For A Broad Array Of Hiv-1 Isolates Using Hybrid Synthetic Peptides
US Patent:
5820865, Oct 13, 1998
Filed:
Sep 18, 1991
Appl. No.:
7/760530
Inventors:
Jay A. Berzofsky - Bethesda MD
Hidemi Takahashi - Tokyo, JP
Ronald N. Germain - Potomac MD
Hidemi Takahashi - Tokyo, JP
Ronald N. Germain - Potomac MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3921
US Classification:
4241881
Abstract:
The instant invention describes the synthesis of short peptides, corresponding to the amino acid residues of the V3 loop of the gpl6O envelope glycoprotein of HIV-1 numbered 315 to 329 by Ratner (Ratner, L. et al. , Nature 313, 277 (1985)) in the strain IIIB, wherein the residue corresponding to number 325 in HIV-1 IIIB is substituted by the homologous residue from another clinical isolate or strain. The invention further describes the use of said peptides in pharmaceutical compositions and an immunization protocol which elicits cytotoxic T cells reactive to a broad range of isolates of HIV-1.
Peptides Stimulating Cytotoxic T Cells Immune To Hiv Rt
US Patent:
5336758, Aug 9, 1994
Filed:
Mar 9, 1990
Appl. No.:
7/489825
Inventors:
Jay A. Berzofsky - Bethesda MD
Anne Hosmalin - Bethesda MD
Mario S. Clerici - Bethesda MD
Ronald N. Germain - Potomac MD
Gene Shearer - Bethesda MD
Bernard Moss - Bethesda MD
Charles D. Pendleton - Bethesda MD
Anne Hosmalin - Bethesda MD
Mario S. Clerici - Bethesda MD
Ronald N. Germain - Potomac MD
Gene Shearer - Bethesda MD
Bernard Moss - Bethesda MD
Charles D. Pendleton - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
A61K 3702, C07K 708
US Classification:
530326
Abstract:
The subject invention relates to a peptide having the amino acid sequence Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro or portions thereof. This peptide is derived from, or based upon, a region of a relatively conserved epitope of HIV-1 reverse transcriptase. The peptide may be utilized in the treatment of patients having human immunodeficiency virus or in the prevention of infection of those individuals who have been exposed to the disease, yet have not become sero-positive. The preparation containing the peptide may be administered either subcutaneously, intramuscularly or intravenously.
T Cell Receptor Ligands And Methods Of Using Same
US Patent:
6900024, May 31, 2005
Filed:
Jul 10, 2002
Appl. No.:
10/193473
Inventors:
Ronald N. Germain - Potomac MD, US
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services - Washington DC
International Classification:
G01N033/53
US Classification:
435 724
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.
T-Cell Receptor Ligands And Methods Of Using Same
US Patent:
5958712, Sep 28, 1999
Filed:
May 19, 1997
Appl. No.:
8/858825
Inventors:
Ronald N. Germain - Potomac MD
Luigi Racioppi - Bethesda MD
Luigi Racioppi - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
G01N 3353
US Classification:
435 724
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.
T Cell Receptor Ligands And Methods Of Using Same
US Patent:
5837477, Nov 17, 1998
Filed:
Jan 15, 1993
Appl. No.:
8/004936
Inventors:
Ronald N. Germain - Potomac MD
Luigi Racioppi - Bethesda MD
Franca Ronchese-Le Gros - Brooklyn, NZ
Luigi Racioppi - Bethesda MD
Franca Ronchese-Le Gros - Brooklyn, NZ
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
and Human Services - Washington DC
International Classification:
C07K 1474, G01N 3350
US Classification:
435 724
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.
T Cell Receptor Ligands And Methods Of Using Same
US Patent:
2001000, Jul 5, 2001
Filed:
Feb 2, 2001
Appl. No.:
09/776522
Inventors:
Ronald Germain - Potomac MD, US
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
International Classification:
G01N033/53, G01N033/555, G01N033/567, C12N005/08
US Classification:
435/007240, 514/002000, 435/372300
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.
T Cell Receptor Ligands And Methods Of Using Same
US Patent:
2001001, Aug 23, 2001
Filed:
Feb 2, 2001
Appl. No.:
09/776520
Inventors:
Ronald Germain - Potomac MD, US
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
Luigi Racioppi - Naples, IT
Franca Ronchese-Le Gros - Wellington, NZ
International Classification:
A61K039/12, G01N033/567
US Classification:
424/199100, 435/007210
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.
T Cell Receptor Ligands And Methods Of Using Same
US Patent:
2002018, Dec 12, 2002
Filed:
Jul 10, 2002
Appl. No.:
10/193474
Inventors:
Ronald Germain - Potomac MD, US
Luigi Racioppi - Bethesda MD, US
Luigi Racioppi - Bethesda MD, US
International Classification:
A61K039/395, C07K016/28
US Classification:
424/144100, 530/388220
Abstract:
The present invention concerns TCR ligands with immunomodulatory properties, as well as methods of identifying such ligands and of using such ligands to modulate T cell effector responses.